Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9516620 | 0.89 | MAPT (0.82) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL6399827 | 0.84 | MAPT (0.75) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL6399316 | 0.84 | MAPT (0.75) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL13511957 | 0.82 | MAPT (0.55) | MAPTKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL23080142 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL3069332 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL18241727 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL3076773 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL16975095 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 | |
| SCHEMBL692819 | 0.81 | MAPT (0.71) | MAPTKMT2AMEN1GPR139ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | claimed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | claimed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | claimed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | KRT18, TYR, MC1R | MAPT 1733/4885KMT2A 579/4885MEN1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.